Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica Communications
Published in: Acta Neuropathologica Communications 1/2013

Open Access 01-12-2013 | Research

Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43

Authors: Rachel H Tan, Claire E Shepherd, Jillian J Kril, Heather McCann, Andrew McGeachie, Ciara McGinley, Andrew Affleck, Glenda M Halliday

Published in: Acta Neuropathologica Communications | Issue 1/2013

Login to get access

Abstract

Background

Two commercially available TDP43 antibodies (phosphorylated or pTDP43, non-phosphorylated or iTDP43) are currently in use for the neuropathological classification of FTLD-TDP cases into pathological subtypes. To date, no studies have performed direct comparisons between these TDP43 antibodies to determine if they identify the same FTLD-TDP subtypes. The reliability of subtype classification with the use of either of these antibodies has also not been investigated. The present study compares the severity of pathological lesions identified with pTDP43 and iTDP43 in a cohort of 14 FTLD-TDP cases, and assesses the accuracy and inter-observer reliability found with either of these antibodies.

Results

pTDP43 identified a greater severity of pathological inclusions across FTLD-TDP cases in comparison to iTDP43 and a higher inter-observer of subtype classification was found with this antibody.

Conclusion

This study demonstrates a higher consistency across independent observers in the pathological subtyping of FTLD-TDP cases with the use of a pTDP43 antibody in comparison to the iTDP43 antibody, and corroborates the use of pTDP43 for pathological classification of FTLD-TDP cases.
Appendix
Available only for authorised users
Literature
1.
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006, 351: 602–611. 10.1016/j.bbrc.2006.10.093CrossRefPubMed
2.
Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, Neary D, Snowden JS, Mann DM: Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol 2006, 112: 539–549. 10.1007/s00401-006-0138-9PubMedCentralCrossRefPubMed
3.
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM: A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011, 122: 111–113. 10.1007/s00401-011-0845-8PubMedCentralCrossRefPubMed
4.
Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VM: Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006, 169: 1343–1352. 10.2353/ajpath.2006.060438PubMedCentralCrossRefPubMed
5.
Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, Lee VM: Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 2009, 117: 137–149. 10.1007/s00401-008-0477-9PubMedCentralCrossRefPubMed
6.
Onodera O, Sugai A, Konno T, Tada M, Koyama A, Nishizawa M: What is the key player in TDP-43 pathology in ALS: disappearance from the nucleus or inclusion formation in the cytoplasm? Neurol Clin Neurophysiol 2013, 1: 11–17.
7.
Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D, Snowden JS, Mann DM: Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007, 113: 521–533. 10.1007/s00401-006-0189-yCrossRefPubMed
8.
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, et al.: Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 2008, 64: 60–70. 10.1002/ana.21425PubMedCentralCrossRefPubMed
9.
Olive M, Janue A, Moreno D, Gamez J, Torrejon-Escribano B, Ferrer I: TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009, 68: 262–273. 10.1097/NEN.0b013e3181996d8fCrossRefPubMed
10.
Schwab C, Arai T, Hasegawa M, Akiyama H, Yu S, McGeer PL: TDP-43 pathology in familial British dementia. Acta Neuropathol 2009, 118: 303–311. 10.1007/s00401-009-0514-3CrossRefPubMed
11.
Grossman M, Wood EM, Moore P, Neumann M, Kwong L, Forman MS, Clark CM, McCluskey LF, Miller BL, Lee VM, Trojanowski JQ: TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol 2007, 64: 1449–1454. 10.1001/archneur.64.10.1449CrossRefPubMed
12.
Josephs KA, Stroh A, Dugger B, Dickson DW: Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol 2009, 118: 349–358. 10.1007/s00401-009-0547-7PubMedCentralCrossRefPubMed
13.
Snowden J, Neary D, Mann D: Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007, 114: 31–38. 10.1007/s00401-007-0236-3CrossRefPubMed
14.
Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, Dickson DW: Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011, 122: 137–153. 10.1007/s00401-011-0839-6PubMedCentralCrossRefPubMed
15.
Armstrong RA, Ellis W, Hamilton RL, Mackenzie IR, Hedreen J, Gearing M, Montine T, Vonsattel JP, Head E, Lieberman AP, Cairns NJ: Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm 2010, 117: 227–239. 10.1007/s00702-009-0350-6PubMedCentralCrossRefPubMed
16.
Armstrong RA, Carter D, Cairns NJ: A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). Neuropathol Appl Neurobiol 2012, 38: 25–38. 10.1111/j.1365-2990.2011.01188.xPubMedCentralCrossRefPubMed
17.
Bieniek KF, Murray ME, Rutherford NJ, Castanedes-Casey M, DeJesus-Hernandez M, Liesinger AM, Baker MC, Boylan KB, Rademakers R, Dickson DW: Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol 2013, 125: 289–302. 10.1007/s00401-012-1048-7PubMedCentralCrossRefPubMed
18.
Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, Wszolek ZK, Ferman TJ, Josephs KA, Boylan KB, et al.: Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011, 122: 673–690. 10.1007/s00401-011-0907-yPubMedCentralCrossRefPubMed
19.
Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujita Y, Takatama M, Okamoto K: Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. Neurosci Lett 2009, 463: 87–92. 10.1016/j.neulet.2009.06.024CrossRefPubMed
20.
Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H: Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 2009, 117: 125–136. 10.1007/s00401-008-0480-1CrossRefPubMed
21.
Dobson-Stone C, Hallupp M, Bartley L, Shepherd CE, Halliday GM, Schofield PR, Hodges JR, Kwok JB: C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology 2012, 79: 995–1001. 10.1212/WNL.0b013e3182684634PubMedCentralCrossRefPubMed
22.
Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, et al.: Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010, 119: 1–4. 10.1007/s00401-009-0612-2PubMedCentralCrossRefPubMed
23.
Luty AA, Kwok JB, Thompson EM, Blumbergs P, Brooks WS, Loy CT, Dobson-Stone C, Panegyres PK, Hecker J, Nicholson GA, et al.: Pedigree with frontotemporal lobar degeneration–motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol 2008, 8: 32. 10.1186/1471-2377-8-32PubMedCentralCrossRefPubMed
24.
Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, et al.: Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007, 61: 427–434. 10.1002/ana.21147CrossRefPubMed
25.
Fleiss J: Measuring nominal scale agreement among many raters. Psychol Bull 1971, 76: 378–382.CrossRef
26.
27.
Landis J, Koch G: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159–174. 10.2307/2529310CrossRefPubMed
Metadata
Title
Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43
Authors
Rachel H Tan
Claire E Shepherd
Jillian J Kril
Heather McCann
Andrew McGeachie
Ciara McGinley
Andrew Affleck
Glenda M Halliday
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2013
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/2051-5960-1-33

Other articles of this Issue 1/2013

Acta Neuropathologica Communications 1/2013 Go to the issue

Research

Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment

Research

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

Research

Reelin immunoreactivity in neuritic varicosities in the human hippocampal formation of non-demented subjects and Alzheimer’s disease patients

Research

ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study

Research

Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies

Research

Human fetal inner ear involvement in congenital cytomegalovirus infection